Mumbai-based cancer hospital, ACTREC and IDRS Labs develop chemotherapy drug

The 6-MP is a chemotherapy drug used in the treatment of Acute Lymphoblastic Leukemia Mumbai-based Tata Memorial Hospital and the Advanced Centre for Training Research and Education in Cancer (ACTREC) of Navi Mumbai, collaborated with IDRS Labs, Bangalore, to develop the first and only oral suspension of 6-mercaptopurine (6-MP) in India. The 6-MP is a chemotherapy drug used in the treatment of Acute Lymphoblastic Leukemia (ALL), the most common type of blood cancer afflicting children. The child-friendly formulation is available in the form of a powder for oral suspension and is marketed under the trade name, PREVALL. PREVALL can be effortlessly reconstituted into a 100 ml oral suspension at a concentration of 10mg/ml. PREVALL is accompanied by a syringe and a Press In Bottle Adapter (PIBA) that allow precise dosing tailored to a patient’s body weight or body surface area. These features not only aid in accurate administration but also mitigate the risk of spillage and caregivers’ exposure to cytotoxic compounds. PREVALL has received approval from Central Drugs Standard Control Organization.